Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies

$ 21.00

4.6 (196) In stock

Triple negative breast tumors contain heterogeneous cancer cells expressing distinct KRAS-dependent collective and disseminative invasion programs

Cancers, Free Full-Text

Current Treatment Landscape and Emerging Therapies for Metastatic Triple-Negative Breast Cancer

Long Non-Coding RNAs in Triple-Negative Breast Cancer

Frontiers Current Triple-Negative Breast Cancer Subtypes

Pharmaceuticals, Free Full-Text

The PTX3/TLR4 autocrine loop as a novel therapeutic target in triple negative breast cancer, Experimental Hematology & Oncology

Treatment landscape of triple-negative breast cancer — expanded options, evolving needs

The PTX3/TLR4 autocrine loop as a novel therapeutic target in triple negative breast cancer, Experimental Hematology & Oncology

Molecular stratification within triple-negative breast cancer subtypes

Frontiers Phenotypic heterogeneity drives differential disease outcome in a mouse model of triple negative breast cancer

Neoadjuvant carboplatin in triple-negative breast cancer: results from NACATRINE, a randomized phase II clinical trial

Cancers, Free Full-Text